Abbott faces trial over claims that preterm infant formula caused dangerous disease
By Brendan Pierson
July 8 (Reuters) -Similac baby formula maker Abbott ABT.N is expected to face a trial on Monday over claims that its formula for preterm infants used in neonatal intensive care units causes a potentially deadly bowel disease, the second trial out of hundreds of similar lawsuits in the United States.
Lawyers for the company and for Illinois resident Margo Gill will make their opening statements to jurors in St. Louis, Missouri, and the trial is expected to last most of the rest of the month. Gill alleges in the lawsuit that her premature infant child developed necrotizing enterocolitis (NEC) as a result of being fed Abbott's products for premature babies.
NEC, which causes the death of bowel tissue, mostly affects newborns and has a fatality rate of between 15% and 40%. Gill's child survived, but suffers long-term health problems, according to the lawsuit.
Like all of the lawsuits over NEC, the case involves formula and products for fortifying mother's milk given to infants in hospital settings, not ordinary formula available to consumers in stores.
"Specialized formulas and fortifiers, like the one in this case, are considered part of the standard of care by the medical community and, along with human milk, are the only available options to feed premature infants," Abbott said in a statement.
The company said that Gill's child "suffered from a traumatic brain injury in utero and at birth, long before she was fed any Abbott products," and that "no one is to blame" for her condition.
Close to 1,000 lawsuits have been filed against Abbott, Enfamil formula maker Reckitt Benckiser RKT.L or both in federal or state courts alleging that cow's milk-based formula products for premature infants caused NEC. More than 500 are centralized in an Illinois federal court, with others pending in Illinois, Missouri and Pennsylvania.
The lawsuits claim that the companies failed to warn that infants given their products are at greater risk of NEC compared to infants who are breast-fed or given donor milk or human milk-derived formula.
Reckitt and a lawyer for the plaintiffs did not immediately comment.
The first lawsuit to go to trial, against Reckitt in Illinois, ended with a $60 million jury verdict in March. Reckitt is appealing that verdict and has argued that the plaintiff's case relied on unsound expert testimony.
The litigation has concerned investors. Reckitt's share price fell about 15% after the verdict, and Abbott's about 4%. Both stocks have remained depressed, although analysts at JPMorgan and Barclays have said they believe the companies' ultimate liability is likely to be small.
The NEC Society, a patient-led non-profit organization working to combat the disease, has criticized the lawsuits, saying that "feeding decisions should be made at patients' bedsides, not in courtrooms." The group has no financial or other relationship with Abbott or Reckitt, according to a spokesperson.
The NEC lawsuits are separate from ongoing litigation against Abbott over the shutdown of its Sturgis, Michigan, plant and subsequent recall of batches of baby formula for possible contamination, which contributed to a nationwide formula shortage in 2022. There have been no trials in those cases.
Reporting By Brendan Pierson in New York, Editing by Alexia Garamfalvi and Josie Kao
면책조항: XM Group 회사는 체결 전용 서비스와 온라인 거래 플랫폼에 대한 접근을 제공하여, 개인이 웹사이트에서 또는 웹사이트를 통해 이용 가능한 콘텐츠를 보거나 사용할 수 있도록 허용합니다. 이에 대해 변경하거나 확장할 의도는 없습니다. 이러한 접근 및 사용에는 다음 사항이 항상 적용됩니다: (i) 이용 약관, (ii) 위험 경고, (iii) 완전 면책조항. 따라서, 이러한 콘텐츠는 일반적인 정보에 불과합니다. 특히, 온라인 거래 플랫폼의 콘텐츠는 금융 시장에서의 거래에 대한 권유나 제안이 아닙니다. 금융 시장에서의 거래는 자본에 상당한 위험을 수반합니다.
온라인 거래 플랫폼에 공개된 모든 자료는 교육/정보 목적으로만 제공되며, 금융, 투자세 또는 거래 조언 및 권고, 거래 가격 기록, 금융 상품 또는 원치 않는 금융 프로모션의 거래 제안 또는 권유를 포함하지 않으며, 포함해서도 안됩니다.
이 웹사이트에 포함된 모든 의견, 뉴스, 리서치, 분석, 가격, 기타 정보 또는 제3자 사이트에 대한 링크와 같이 XM이 준비하는 콘텐츠 뿐만 아니라, 제3자 콘텐츠는 일반 시장 논평으로서 "현재" 기준으로 제공되며, 투자 조언으로 여겨지지 않습니다. 모든 콘텐츠가 투자 리서치로 해석되는 경우, 투자 리서치의 독립성을 촉진하기 위해 고안된 법적 요건에 따라 콘텐츠가 의도되지 않았으며, 준비되지 않았다는 점을 인지하고 동의해야 합니다. 따라서, 관련 법률 및 규정에 따른 마케팅 커뮤니케이션이라고 간주됩니다. 여기에서 접근할 수 있는 앞서 언급한 정보에 대한 비독립 투자 리서치 및 위험 경고 알림을 읽고, 이해하시기 바랍니다.
